| Name | Title | Contact Details |
|---|---|---|
Richard Utter |
Senior Director of Information Technology and Information Security Officer | Profile |
Manish Nautiyal |
Director of Information Technology, Claims and Data Management Operations | Profile |
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.
Accredited by The Joint Commission, Stanly Regional is governed by a volunteer board of directors representing both Stanly and Montgomery counties. Our main campus is a 109-bed medical facility consisting of 97 general acute beds, 10 rehabilitation beds and 12 behavioral health beds. With a staff of healthcare professionals using the latest medical treatments and technology, Stanly Regional Medical Center offers advancements in cancer treatment, imaging, rehabilitation, women`s services and more. For outstanding medical care from professionals you know and trust, look no further. We`re right beside you.
Barbara Davis Ct Chldhd Diabts is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.
River Garden Hebrew Home is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. River Garden Hebrew Home is based in Jacksonville, FL. You can find more information on River Garden Hebrew Home at www.rivergarden.org